These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 30005954)
1. Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of van den Bosch S; Dijkema T; Philippens MEP; Terhaard CHJ; Hoebers FJP; Kaanders JHAM; Oyen WJG Radiother Oncol; 2019 Jan; 130():39-45. PubMed ID: 30005954 [TBL] [Abstract][Full Text] [Related]
2. Use of Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718 [No Abstract] [Full Text] [Related]
3. Impact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and Radiotherapy Planning in Head and Neck Squamous Carcinoma: A Retrospective Study of 46 Patients. Pham A; Garai I; Árpád K; Dér Á; Szanto E; Hascsi Z; Bátyi F; Berényi E; Pham TM Med Sci Monit; 2024 Jan; 30():e942122. PubMed ID: 38243589 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma. Gupta T; Chatterjee A; Rangarajan V; Purandare N; Arya S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):162-170. PubMed ID: 31496204 [TBL] [Abstract][Full Text] [Related]
6. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial. Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593 [TBL] [Abstract][Full Text] [Related]
7. Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within. Kruse V; Mees G; Maes A; D'Asseler Y; Borms M; Cocquyt V; Van De Wiele C Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):462-8. PubMed ID: 24695005 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of diffusion-weighted imaging and Noij DP; Martens RM; Zwezerijnen B; Koopman T; de Bree R; Hoekstra OS; de Graaf P; Castelijns JA Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267 [TBL] [Abstract][Full Text] [Related]
9. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422 [TBL] [Abstract][Full Text] [Related]
10. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status. Moan JM; Amdal CD; Malinen E; Svestad JG; Bogsrud TV; Dale E Radiother Oncol; 2019 Nov; 140():54-61. PubMed ID: 31177043 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822 [TBL] [Abstract][Full Text] [Related]
12. Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR. Rasmussen JH; Fischer BM; Aznar MC; Hansen AE; Vogelius IR; Löfgren J; Andersen FL; Loft A; Kjaer A; Højgaard L; Specht L Br J Radiol; 2015 Apr; 88(1048):20140655. PubMed ID: 25634069 [TBL] [Abstract][Full Text] [Related]
13. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary? Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285 [TBL] [Abstract][Full Text] [Related]
14. Use of Diffusion-Weighted Imaging and Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343 [TBL] [Abstract][Full Text] [Related]
15. Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes. Perez-Romasanta LA; Bellon-Guardia M; Torres-Donaire J; Lozano-Martin E; Sanz-Martin M; Velasco-Jimenez J Clin Transl Oncol; 2013 Apr; 15(4):283-93. PubMed ID: 22865325 [TBL] [Abstract][Full Text] [Related]
16. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596 [TBL] [Abstract][Full Text] [Related]
18. The importance of FDG-PET/CT parameters for the assessment of the immune status in advanced HNSCC. Ohashi T; Terasawa K; Aoki M; Akazawa T; Shibata H; Kuze B; Asano T; Kato H; Miyazaki T; Matsuo M; Inoue N; Ito Y Auris Nasus Larynx; 2020 Aug; 47(4):658-667. PubMed ID: 32089351 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of textural indices extracted from pretherapeutic 18-F FDG-PET/CT in head and neck squamous cell carcinoma. Guezennec C; Robin P; Orlhac F; Bourhis D; Delcroix O; Gobel Y; Rousset J; Schick U; Salaün PY; Abgral R Head Neck; 2019 Feb; 41(2):495-502. PubMed ID: 30549149 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility of Ha SC; Roh JL; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY Acta Otolaryngol; 2019 Sep; 139(9):810-815. PubMed ID: 31274365 [No Abstract] [Full Text] [Related] [Next] [New Search]